BBSRC Portfolio Analyser
Award details
BBSRC-funded studentship: Next generation vaccine for bluetongue virus (BTV) type 8 and the immune response in animals
Reference
BBS/E/I/00001351
Principal Investigator / Supervisor
Professor Peter Mertens
Co-Investigators /
Co-Supervisors
Institution
The Pirbright Institute
Department
The Pirbright Institute Department
Funding type
Research
Value (£)
15,900
Status
Completed
Type
Institute Project
Start date
01/10/2007
End date
31/03/2012
Duration
54 months
Abstract
Bluetongue virus (BTV) is the etiological agent of bluetongue (BT), an economically important disease of domesticated livestock. Since 1998 nine distinct strains of BTV have entered Europe, killing over 1.8 million animals. Live attenuated vaccine strains are available but are unsuitable for use in Europe, causing severe disease in local sheep breeds. Inactivated BTV vaccines have been developed for BTV-2 and 4, but are not available for BTV-8, (Holland, Belgium, France and Germany; August 2006). The Arbovirus Research group has already obtained funding from BBSRC/Defra for the initial development of safe, effective and stable, next-generation BTV vaccines, based on recombinant baculovirus, vaccinia virus, DNA and/or bacterial expression. The Ph.D project will generate additional constructs for the expression of BTV-8 proteins (based on systems already constructed for BTV-4). It will then help to evaluate the immune response to the individual BTV proteins in mice.
Summary
unavailable
Committee
Not funded via Committee
Research Topics
Animal Health, Immunology, Microbiology
Research Priority
X – Research Priority information not available
Research Initiative
X - not in an Initiative
Funding Scheme
X – not Funded via a specific Funding Scheme
I accept the
terms and conditions of use
(opens in new window)
export PDF file
back to list
new search